Literature DB >> 31148214

CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.

Torbjørn Kråkenes1, Ida Herdlevaer1,2, Margrethe Raspotnig1, Mette Haugen2, Manja Schubert2, Christian A Vedeler1,2,3.   

Abstract

The pathogenesis of Yo-mediated paraneoplastic cerebellar degeneration (PCD) is unclear. We applied cerebrospinal fluid and serum from PCD patients as well as CDR2 and CDR2L antibodies to neuronal tissue, cancer cell lines, and cells transfected with recombinant CDR2 and CDR2L to elucidate which is the major antigen of Yo antibodies. We found that Yo antibodies bound endogenous CDR2L, but not endogenous CDR2. However, Yo antibodies can bind the recombinant CDR2 protein used in routine clinical testing for these antibodies. Because Yo antibodies only bind endogenous CDR2L, we conclude that CDR2L is the major antigen of Yo antibodies in PCD. ANN NEUROL 2019;86:316-321.
© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

Entities:  

Year:  2019        PMID: 31148214     DOI: 10.1002/ana.25511

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

1.  Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.

Authors:  Elise Peter; Isabelle Treilleux; Valentin Wucher; Emma Jougla; Alberto Vogrig; Daniel Pissaloux; Sandrine Paindavoine; Justine Berthet; Géraldine Picard; Véronique Rogemond; Marine Villard; Clémentine Vincent; Laurie Tonon; Alain Viari; Jérôme Honnorat; Bertrand Dubois; Virginie Desestret
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-07-12

Review 2.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

3.  Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.

Authors:  Laura C Hurley; Nancy K Levin; Madhumita Chatterjee; Jasmine Coles; Shlomo Muszkat; Zachary Howarth; Gregory Dyson; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2020       Impact factor: 4.388

4.  A proteolytic method for evaluating O-GlcNAcylation on proteins of similar molecular weight to antibody heavy chain after immunoprecipitation.

Authors:  Miranda Machacek; Patrick E Fields; Chad Slawson
Journal:  Anal Biochem       Date:  2020-10-28       Impact factor: 3.365

5.  Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.

Authors:  Ida Herdlevær; Mette Haugen; Kibret Mazengia; Cecilie Totland; Christian Vedeler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-02-02

6.  Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy.

Authors:  Christopher M Bartley; Neelroop N Parikshak; Thomas T Ngo; Jessa A Alexander; Kelsey C Zorn; Bonny A Alvarenga; Min K Kang; Massimo Pedriali; Samuel J Pleasure; Michael R Wilson
Journal:  Front Neurol       Date:  2021-10-22       Impact factor: 4.003

7.  High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display.

Authors:  Brian O'Donovan; Caleigh Mandel-Brehm; Sara E Vazquez; Jamin Liu; Audrey V Parent; Mark S Anderson; Travis Kassimatis; Anastasia Zekeridou; Stephen L Hauser; Sean J Pittock; Eric Chow; Michael R Wilson; Joseph L DeRisi
Journal:  Brain Commun       Date:  2020-08-03

8.  The Diagnostic Value of Onconeural Antibodies Depends on How They Are Tested.

Authors:  Raquel Ruiz-García; Eugenia Martínez-Hernández; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

9.  Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.

Authors:  Benoît Déchelotte; Sergio Muñiz-Castrillo; Bastien Joubert; Alberto Vogrig; Géraldine Picard; Véronique Rogemond; Anne-Laurie Pinto; Christine Lombard; Virginie Desestret; Nicole Fabien; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-13

10.  Identification of a 9-gene prognostic signature for breast cancer.

Authors:  Zelin Tian; Jianing Tang; Xing Liao; Qian Yang; Yumin Wu; Gaosong Wu
Journal:  Cancer Med       Date:  2020-10-14       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.